Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00108017 | Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) | PHASE3 | COMPLETED | 330 | — | — | Apr 1, 2005 | Jul 1, 2006 | May 13, 2015 | - | — |
| NCT00832377 | COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED) | PHASE2 | COMPLETED | 37 | — | — | Apr 24, 2009 | Mar 26, 2010 | Sep 29, 2017 | - | — |
The therapeutic goal of normal tension glaucoma treatment includes lowering IOP to prevent progression of damage in optic nerves or vision. In this trial, IOP was measured with the same tonometer throughout the study. A decreased IOP from baseline is considered an improvement. IOP was measured in both eyes and the eye with the higher IOP was used for the participant.
| Arm | Type | Description |
|---|---|---|
| Timolol/Dorzolamide | EXPERIMENTAL | Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks |
| Name | Type | Description |
|---|---|---|
| MK0507A, dorzolamide hydrochloride (+) timolol maleate | DRUG | - |
| Comparator: timolol maleate | DRUG | - |
| Duration of Treatment: Part 1) 6 wk timolol maleate run in | DRUG | - |
| Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds | DRUG | - |
| timolol/dorzolamide combination | DRUG | Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks |
Inclusion Criteria: * Patients with glaucoma or ocular hypertension Exclusion Criteria: * Other eye conditions * Poor vision * Recent eye surgery * Use of contact lenses * Nursing or pregnant women * Use of some other selected medications * Drug or alcohol abuse * Asthma * Slow heart beat * Aller...